Diabetes drug trial hits goal

According to reports in the diabetes news, diabetes drug company AtheroGenics Inc. have claimed that their experimental diabetic drug AGI-1067 has passed main goals in clinical trials . The drug has apparently helped to treat people with type 2 diabetes by reducing blood glucose levels.
The trial, called ANDES, is investigating two different dosages of the drug, 75mg and 150mg. The company will now continue to analyse the trial data, and conduct a further additional trial in line with Food and Drug Administration development plan.
Industry reports indicate that AtheroGenics are in discussion with various potential partners, but the Chief Executive of the company warned that he could not give further details until anything was confirmed.

To Top